Meeting
2012 ASCO Annual Meeting
Surgery for patients receiving ipilimumab: Safety profile and immunological insights.
Authors
David E. Gyorki
Memorial Sloan-Kettering Cancer Center, New York, NY
David E. Gyorki , Jianda Yuan , Zhenyu Mu , Bushra Zaidi , Humilidad F. Gallardo , Mary Susan Brady , Philip H. Gutin , Daniel G. Coit , Jedd D. Wolchok , Charlotte Eielson Ariyan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Melanoma
Citation
J Clin Oncol 30, 2012 (suppl; abstr 8583)
DOI
10.1200/jco.2012.30.15_suppl.8583
Abstract #
8583
Poster Bd #
37A
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
A pilot study of preoperative, single-dose ipilimumab (Ipi) and/or cryoablation (Cryo) in women (pts) with early stage/resectable breast cancer (ESBC).
First Author: Adi Diab
Poster
2024 ASCO Annual Meeting
ADU-1604, a novel CTLA-4 blocking antibody, to modulate pharmacodynamic markers in patients with PD1 relapse/refractory melanoma.
First Author: Guillermo De Velasco
Poster
2019 ASCO Annual Meeting
A phase I, first-in-human, open label, dose-escalation and cohort expansion study of MGD019, a bispecific DART protein binding PD-1 and CTLA-4 in patients with unresectable or metastatic neoplasms.
First Author: Jason J. Luke
Poster
2016 ASCO Annual Meeting
A phase Ib study combining the second-generation DNA hypomethylating agent (DHA) guadecitabine (SGI-110) and ipilimumab in patients with metastatic melanoma: the NIBIT-M4 Study.
First Author: Anna Maria Di Giacomo